Landscapes / Companies
Ocugen not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 3
1 in Phase 2
Drugs
4
in active trials · 7 in all
Trials
4 active
8 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | 30 Jul 2028Phase 3 trial completes | |||
| Next date | 30 Jul 2028 · Phase 3 trial completes | ||||
| Also tested for | Dry Age-related Macular Degeneration | ||||
| Open drug page | |||||
— |
Phase 2/3 | — | |||
| Also tested for | Stargardt Disease | ||||
| Open drug page | |||||
— |
Phase 1/2 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Retinitis Pigmentosa, Leber Congenital Amaurosis | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Center Involved Diabetic Macular Edema, Diabetic Macular Edema | ||||
| Open drug page | |||||
About
- No active trial
- BBV152, Brimonidine Mono Therapy, Corticosteroid Eye Drop
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021